Saccharomyces cerevisiae cells treated with the immunosuppressant rapamycin or depleted for the targets of rapamycin TOR1 and TOR2 arrest growth in the early Gi phase of the cell cycle. Loss of TOR function also causes an early inhibition of translation initiation and induces several other physiological changes characteristic of starved cells entering stationary phase (GO). A Gi cyclin mRNA whose translational control is altered by substitution of the UBI4 5' leader region (UBI4 is normally translated under starvation conditions) suppresses the rapamycin-induced Gl arrest and confers starvation sensitivity. These results suggest that the block in translation initiation is a direct consequence of loss of TOR function and the cause of the Gl arrest. We propose that the TORs, two related phosphatidylinositol kinase homologues, are part of a novel signaling pathway that activates eIF-4E-dependent protein synthesis and, thereby, Gl progression in response to nutrient availability. Such a pathway may constitute a checkpoint that prevents early Gl progression and growth in the absence of nutrients.
INTRODUCTION
The immunosuppressant rapamycin and the related compound FK506 exert their immunosuppressive effects by inhibiting intermediate steps in signal transduction that lead to T cell activation and proliferation (Heitman et al., 1991; Schreiber and Crabtree, 1992;  Sigal and Dumont, 1992; Liu, 1993; Fruman et al., 1994) . FK506 in complex with its intracellular receptor FKBP inhibits the Ca21 /calmodulin-dependent phosphatase calcineurin. As a downstream effector of the T cell receptor (TCR), calcineurin normally triggers nuclear import of a subunit of the transcription factor NF-AT which, in turn, activates 50-100 genes, including the gene encoding the lymphokine interleukin-2 (IL-2) (Weiss and Littman, 1994) . Rapamycin also forms a toxic complex with FKBP, but instead of inhibiting the TCR signaling pathway, inhibits a subsequent signal transduction cascade that is stimulated by IL-2 (Bierer et al., 1990; Dumont et al., 1990) . The IL-2 signaling pathway mediates Gl progression (pro-known for its inhibition of IL-2-dependent p70 S6 kinase activation, rapamycin also inhibits p70 S6 kinase activation in response to these other mitogens Chung et al., 1992 Chung et al., , 1994 Price et al., 1992) . The p70 S6 kinase phosphorylates the ribosomal protein S6 which, in turn, leads to the activation of translation initiation Thomas, 1992;  Jefferies et al., Terada et al., 1994) . The p70 S6 kinase thus links mitogenic stimulation and the initiation of protein synthesis. A homologue of the yeast TOR proteins (FRAP/RAFT1 /RAPT1 /mTOR) (see below) has recently been identified in mammalian cells as a direct target of the rapamycin-FKBP complex pathway (for a figure that summarizes the pathway, see Downward, 1994) .
In the yeast Saccharomyces cerevisiae, rapamycin-FKBP inhibits the TOR1 and TOR2 gene products and arrests cells with an unbudded morphology, indicative of a Gi cell cycle arrest similar to that observed in T cells (Heitman et al., 1991; Cafferkey et al., 1993; Helliwell et al., 1994; Stan et al., 1994; Zheng et al., 1995) . A dominant point mutation in either TOR gene renders a cell resistant to rapamycin, whereas disruption of both genes results in an unbudded morphology, similar to that seen when wild-type cells are treated with rapamycin, and a ln DNA content (Heitman et al., 1991; Cafferkey et al., 1993; Helliwell et al., 1994) . TOR1 and TOR2 are large , functionally homologous proteins that are structurally related to phosphatidylinositol kinases (PI kinases) Garcia-Bustos et al., 1994; Helliwell et al., 1994; Yoshida et al., 1994) . PI kinases are required for production of phosphatidylinositol-derived second messengers (Carpenter and Cantley, 1990) . Thus, TOR1 and TOR2, like FRAP/RAFT1/RAPT1/mTOR, may be components of a rapamycin-sensitive signaling pathway required for cell cycle progression in Gi.
In S. cerevisiae, the decision to commit to a cell cycle is made at a point in late Gi termed START. Traversal of START and entry into S phase is regulated by the activity of the cyclin-dependent kinase encoded by CDC28 (Reed, 1992; Nasmyth, 1993) . Three Gl-specific cyclin genes were originally identified and named CLN1, CLN2, and CLN3 (Cross, 1988; Nash et al., 1988; Richardson et al., 1989; Wittenberg et al., 1990) ; additional candidate Gl cyclin genes have subsequently been identified and named HCS26, ORFD, CLB5, and CLB6 (Frohlich et al., 1991; Ogas et al., 1991; Epstein and Cross, 1992; Kuehne and Linder, 1993; Schwob and Nasmyth, 1993) . All except CLN3 are transcribed only in late Gl with CLN1, CLN2, and HCS26, and possibly ORFD, under control of the transcription factor SBF. CLN3, whose transcript is present throughout the cell cycle, is regulated post-transcriptionally and acts as an upstream activator of other Gl cyclins (Nasmyth and Dirick, 1991; Ogas et al., 1991; Tyers et al., 1992 Tyers et al., , 1993 Cvrckova and Nasmyth, 1993) .
When nutrients are limiting, haploid yeast cells do not proceed to START in late Gi, but instead exit the mitotic cell cycle in early Gl and enter a stationary or GO phase (for review see Werner-Washburne et al., 1993) . Stationary phase enables a cell to maintain viability for long periods when nutrients are not available, and is characterized by several physiological properties including ln DNA content, failure to reach START, reduced protein synthesis, accumulation of glycogen, acquisition of thermotolerance, and changes in the pattern of transcription (Werner-Washburne et al., 1993) . Nutrient sensing and the regulation of entry into stationary phase are poorly understood, but are generally thought to involve the RAS/cAMP pathway (Broach, 1991; Thevelein, 1994) . However, this is not the sole nutrient-sensing pathway, as mutants in the RAS/cAMP pathway have been isolated that exhibit a normal response to starvation independently of intracellular cAMP levels (Cameron et al., 1988 ).
Here we report that cells lacking TOR function (cells treated with rapamycin or depleted of TOR) arrest growth and rapidly exhibit, by all criteria examined, properties diagnostic of GO or stationary phase, including a reduction in translation initiation. The cell cycle arrest upon loss of TOR function is suppressed by altering the translational control of the Gl cyclin CLN3. Our results and analogy with mammalian cells suggest that TOR is part of a novel signal transduction pathway required for translation initiation and Gi progression, perhaps in response to nutrients.
MATERIALS AND METHODS Strains, Plasmids, and Media
The parental strain in this study was JK9-3da (MATa leu2-3, 112 ura3-52 trpl his4 rmel HMLa). Isogenic derivatives with only the changes indicated are shown in Table 1 . The composition of rich medium (YPD), synthetic galactose/glycerol medium (SGal/Gly), and synthetic glucose medium (SD) supplemented with the appropriate nutrients was as described (Sherman, 1991) . All cultures were incubated at 30'C unless otherwise indicated. Rapamycin (provided by Sandoz Pharma, Basel, Switzerland) was added to the medium to a final concentration of 0.2 ,ug/ml. Rapamycin was diluted into media from a stock solution of 1 mg/ml in 10% Tween-20/90% ethanol (Heitman et al., 1993) . Plasmid pJK5 contains the entire TOR2 gene under control of the GALI promoter . YEplac181::tor2-61ts (ampr 2 ,. LEU2) contains the entire TOR2 gene and was isolated by hydroxylamine mutagenesis as a temperaturesensitive TOR2 allele (Barbet and Hall, unpublished data) . The RAS2va119 allele on plasmid YEp213 (ampr 2 ,u URA3) (Broek et al., 1987) was transformed into JK9-3da. YCplaclll is ampr CEN4 LEU2 (Gietz and Sugino, 1988) . The BCY1 gene was disrupted (bcyl::URA3) as described using the one-step gene replacement technique Rothstein, 1991 (Nasmyth and Dirick, 1991) at the ura3 locus was achieved by linearizing the plasmid containing the CLN2 construct with EcoRV. Disruptions and integrations were confirmed by Southern blot analysis. All transformations were performed using the lithium acetate procedure (Ito et al., 1983) .
Flow Cytometry
Overnight cultures of yeast in SD complete medium were diluted to OD600 <0.05 and allowed to grow before the addition of rapamycin at OD600 = 0.2. Three hundred-microliter samples were taken from these cultures at hourly intervals, sonicated for 2 min, and immediately fixed by addition of 700 ,ul absolute ethanol. Samples were incubated overnight at 4°C, washed, and resuspended in 50 mM sodium citrate, pH 7.4, and treated with RNAse (0.25 mg/ml) for 1 h at 37°C. DNA was stained by the addition of 500 ,ul citrate buffer containing 16 ,ug/ml propidium iodide. For each timepoint taken, 10,000 events were analyzed for DNA content using a Becton Dickinson FACScan (Mountain View, CA) and data was processed using Lysys II software (Lincoln Park, NJ).
Order-of-Function Mapping
A reciprocal shift experiment was performed with the temperaturesensitive tor2 strain NB35 and a-factor as described (Hereford and Hartwell, 1974) and also with the modification of a 1.5-h overlap in which both blocks were imposed. Because the effects of rapamycin are irreversible (presumably because the drug cannot be washed out) we were unable to perform a standard reciprocal shift experiment with a-factor and rapamycin. To circumvent this problem, we performed a double block experiment and an a-factor to rapamycin shift experiment. For the double block experiment, logarithmically growing cultures of JK9-3da in SD medium were treated with nocodazole (10 jig/ml; Sigma, St. Louis, MO) for 2.5 h to arrest the cells in mitosis. Cells were harvested by filtration and nocodazole was washed out of the cells with 10 volumes of sterile water followed by 10 volumes of SD medium. Cells were then incubated in fresh SD medium either with no addition, with 10 jig/ml mating pheromone (a-factor), with 0.2 jtLg/ml rapamycin, or with both mating pheromone and rapamycin. Samples were taken at 30-min intervals, sonicated for 2 min to separate cells, and scored for emergence of buds and appearance of the shmoo phenotype (Sprague, 1991) . For the a-factor to rapamycin shift experiment, logarithmically growing cultures of JK9-3da in SD medium were treated with 10 ,ug/ml a-factor for 2.5 h. Cells were harvested by filtration and washed with 10 volumes of sterile water followed by 10 volumes of SD medium. The culture was then split; one half of the culture received 0.2 ,tg/ml rapamycin and the other half received drug vehicle alone. Samples were removed at 30 min intervals, sonicated for 2 min, and scored for the emergence of buds.
Northern Analysis
Extraction of total cellular RNA was performed as previously described (Jensen et al., 1983) . For Northern analysis, 10 ,ug of total RNA was separated on 1% agarose gels containing 6% formaldehyde, and transferred overnight to Hybond-N+ nylon membrane (Nash et al., 1988) . The probe for CLNI was a 2-kbp HindIll fragment from pclnl::URA3 (Hadwiger et al., 1989) . The probe for CDC28 was a 1.2-kbp XhoI/XbaI fragment from YEpl3::CDC28 (gift of K. Nasmyth). The probe for TORI was a 4.3-kbp HindIll fragment from pPW20 (Helliwell et al., 1994) . The TOR2 probe was a 5.3-kbp BglII fragment from pJK3-3 Nasmyth) , which consists of a 7-kb genomic BglII fragment containing the CLN3 gene inserted into YEp352. For the asynchronous flow cytometry experiments, strains were grown in SD medium minus leucine to early log phase, and treated with 0.2 ,ug/ml rapamycin. Cell number and DNA content were analyzed hourly for 5 h following rapamycin treatment. For the synchrony experiments, NB36 and NB37 were grown to early log phase, then treated with 10 ,Lg/ml a-factor for 2.5 h to arrest cells at start. a-Factor was removed by filtration and washing with water, followed by SD medium minus leucine, and cells were resuspended in fresh SD medium minus leucine. Samples were removed at 20-min intervals, washed, sonicated to separate cells, and assessed for emergence of buds and DNA content (flow cytometry). At maximal budding (generally 60 min after release from a-factor), the cultures were split; half received 0.2 ,ug/ml rapamycin, the remaining half received drug vehicle alone. Flow cytometry was performed as described above.
Assay of Starvation Sensitivity
Strain NB36 containing the UBI4-CLN3 fusion and control strain NB37 containing the UBI4 5' region without the CLN3 open reading frame, on a LEU2 plasmid, were grown in SD medium minus leucine for 6 days. Samples were removed daily and assessed for cell number/milliliter of culture, cell viability, and percentage of budded cells. For viability determination, 103 cells were plated on rich medium (YPD) in duplicate, and the number of cells able to form colonies was determined as a percentage of total number of cells plated. Replica plating to SD medium minus leucine showed that over 80% of the cells retained their respective plasmid, even after prolonged incubation.
RESULTS

Rapamycin Blocks Gl Progression
We have shown previously that rapamycin treatment causes yeast cells to arrest with an unbudded morphology (Heitman et al., 1991; . Such a phenotype, although suggestive of, is not necessarily indicative of a Gi arrest, as mutants have been isolated that are perturbed in budding but not in the onset of DNA synthesis (Adams et al., 1990; Johnson and Pringle, 1990; Bender and Pringle, 1991; Cvrckova and Nasmyth, 1993) . We therefore examined whether yeast cells treated with rapamycin arrest with a ln DNA content, and are thus indeed impaired in Gl progression. An exponentially growing asynchronous culture of the haploid strain JK9-3da was treated with 0.2 ,ug/ml rapamycin, and at hourly intervals samples were removed for flow cytometry. As shown in Figure  1 , a shift to a ln DNA content was observed after 1 h of rapamycin treatment, and after 2-3 h, -85% of the cells contained a ln DNA complement ( Figure 1D ). The shift to ln DNA content paralleled growth arrest; rapamycin-treated cells never completed more than one doubling, as determined by direct counting of the cells in the treated culture at the different time intervals. A control culture treated with the drug vehicle alone (10% Tween/90% ethanol) continued to grow normally, doubling in cell number every 125 min for the duration of the experiment. Thus, rapamycin causes a Gi arrest within one generation. As shown* previously, TOR depletion also causes cells to arrest growth with a ln DNA content (Helliwell et al., 1994) . When the size distribution of cells was analyzed, we observed two subpopulations in the rapamycintreated cells ( Figure 1E ). The major subpopulation of cells increased in size throughout the experiment, whereas the minor subpopulation of cells appeared to remain as small cells. Although the two subpopulations became more evident at later time points as the larger cells continued to increase in volume, two discrete populations could already be discerned after 2 h. The small cells most likely represent newly formed, starved daughter cells (see below) (Johnston et al., 1977) . The increased size of the larger cells can be accounted for by the observation that they contain an exceptionally large vacuole (Heitman et al., 1991) . Because an enlarged vacuole is also symptomatic of starvation (Granot and Snyder, 1991) , these cells might also be starved (in GO) despite the presence of nutrients. The reason for the biphasic size distribution is unclear.
The TOR Restriction Point Is in Early Gl
Before START To determine the TOR restriction point within Gl, we performed an order-of-function (reciprocal shift) analysis using a temperature-sensitive tor mutant and the mating pheromone a-factor (Hereford and Hartwell, 1974) . This maps the TOR restriction point relative to START, the a-factor arrest point. The mutant strain (NB35) used in this experiment contained a temperature-sensitive tor2 allele on a plasmid and chromosomal disruptions of both TOR1 and TOR2. NB35 Figure 2B ). Budding after shift from a-factor to the restrictive temperature was not due to a slow inactivation of temperature-sensitive TOR.
First, NB35 (torts) arrests within one generation. Second, shifting cells to the nonpermissive temperature 1.5 h before release from the a-factor block did not prevent budding ( Figure 2C ). Third, wild-type cells released from an a-factor block into medium containing rapamycin also resumed budding ( Figure  2D ). The results of a double block experiment performed with a-factor and rapamycin (see MATERI-ALS AND METHODS) were also consistent with a TOR restriction point in early Gl; rapamycin prevented nocodazole-synchronized cells from forming shmoos in response to a-factor (our unpublished results). Thus, the TOR restriction point is in early Gl before START. As further evidence that loss of TOR function causes an early Gl arrest, we observed that rapamycin-treated cells lack START-specific transcripts encoding the Gl cyclins (Figure 3) (Figure 3 and our unpublished results for CLN2) were no longer detectable after 2 h of rapamycin treatment. Surprisingly, the normally constitutively expressed CLN3 transcript was also reduced with similar kinetics as seen for CLN1 and CLN2, but was not completely eliminated. As determined by densitometry of appropriately exposed autoradiographs and normalization to ACTI transcript levels, the CLN3 mRNA level was maximally reduced by -60%. The mRNAs for the three additional genes, HCS26, ORFD, and CLB5, which bear limited homology to the CLN genes and are also expressed only in late Gi also disappeared upon rapamycin treatment, with kinetics identical to those seen for the CLN1 and CLN2 transcripts (Figure 3 for HCS26 and ORFD) .
Expression of the CLN1, CLN2, and HCS26 genes (and possibly ORFD) is under control of the transcription factor SBF, which is composed of the DNA binding moiety SWI4 and its regulatory subunit SWI6 (Nasmyth and Dirick, 1991; Ogas et al., 1991) . We therefore assessed the levels of SW14 and SWI6 transcripts in rapamycin-treated cells. Normally, the mRNA for SWI6 is constitutively expressed whereas the mRNA for SWI4 oscillates, peaking in late Gl and falling to a low but detectable basal level elsewhere in the cell cycle (Breeden and Mikesell, 1991) . Like the CLN3 transcript, the mRNA for SW16 was depleted by -60% (Figure 3) . The transcript for SWI4 fell to basal levels 2 h after rapamycin treatment, thus behaving like other START-specific mRNAs. These observations are not due to a global repression of transcription as the transcripts for actin (ACTI) and CDC28 and also the previously identified targets of rapamycin TOR1 and TOR2 were not depleted throughout the time course of these experiments (Figure 3 and our unpublished results) . Furthermore, some transcripts are actually induced upon rapamycin treatment (see below). As mentioned above, the absence of START-specific transcripts upon rapamycin treatment is presumably an indirect consequence of a cell cycle arrest before START (Hubler et al., 1993) . The reduction in the normally constitutive messages could reflect the inherent instability of untranslated (see below) mRNAs.
TOR Is Required for Translation Initiation
Because rapamycin blocks activation of protein synthesis in mammalian cells (Jefferies et al., 1994; Terada et al., 1994) and because inhibition of protein synthesis in yeast causes an early Gl arrest (Hartwell and Unger, 1977; Pringle and Hartwell, 1981; Brenner et al., 1988) , we investigated whether rapamycin blocks protein synthesis in yeast by assaying incorporation of
[35S]methionine at intervals after addition of rapamycin. We observed an early decrease in incorporation upon rapamycin treatment ( Figure 4A ). Protein synthesis fell to a low (-10% of normal levels) but detectable level after 120 min, and remained at this low level throughout the course of the experiment. The low level of protein synthesis was greater than that observed in cells treated with cycloheximide (100 ,tg/ ml), which reduced protein synthesis to undetectable levels. Up to 100-fold higher concentrations of rapamycin did not have a more severe effect on incorporation. Protein synthesis was not affected in a rapamycin-resistant TORI-i (JH11-lc) or TOR2-1 (JH12-17b) mutant, as assayed by [35S] methionine incorporation in the presence of rapamycin. Thus, rapamycin is an effective inhibitor of protein synthesis acting through TOR.
To confirm that TOR is required for protein synthesis, as suggested by the above observation, we examined the effect of TOR depletion on protein synthesis. The torts strain NB35 was shifted to the nonpermissive temperature and levels of protein synthesis were determined at time intervals after the temperature shift. At the nonpermissive temperature, we observed a progressive decrease in the levels of [35S]methionine incorporation ( Figure 4B ). Incorporation levels fell to a minimum of -10% after 6 h of incubation at the nonpermissive temperature. Levels tion of protein synthesis causes an early Gl arrest (Hartwell and Unger, 1977; Pringle and Hartwell, 1981; Brenner et al., 1988) , the protein synthesis defect may be the cause of the cell cycle arrest; the relatively slow inhibition of incorporation in NB35 (torts) at the nonpermissive temperature, compared with rapamycin-treated cells at the permissive temperature, is not necessarily inconsistent with the first cycle arrest of NB35 (torts) because this strain has a translation defect even at the permissive temperature and because cells have a longer cell cycle at the higher temperature.
To determine whether the inhibition of protein synthesis was at the level of initiation or elongation, polysome profiles of wild-type cells treated with rapamycin for 1 and 2 h were analyzed. This experiment was performed in the absence of the translation elongation inhibitor cycloheximide so that a block in elongation, if imposed, could be observed. Such a block is characterized by an accumulation of polysomes. No polysomes were present in either extract, only a single peak corresponding to 80S monosomes and ribosomes (our unpublished results). Rapamycin does not, therefore, cause a translation elongation block; however, a mild defect in the rate of elongation that is not sufficiently stringent to prevent ribosome "run-off" during the time needed to harvest, wash, and lyse cells in preparation for sucrose gradients would not be detected. To investigate whether rapamycin causes a block in translation initiation, wild-type cells were treated with drug vehicle alone or with rapamycin for 1 and 2 h followed by a 10-min treatment with cycloheximide to prevent run-off of any polysomes present ( Figure 5 , A and B; our unpublished result for 1-h timepoint). Rapamycin treatment caused a progressive decay of polysomes with a coincident increase in the 80S peak, indicating an initiation block. The apparent discrepancy between the observed inhibition of [35S]methionine incorporation (-90%) and the inhibition of polysomes (-60%) after 2 h of rapamycin treatment may reflect a difference in the sensitivities of the two assays or a mild elongation defect in addition to a block in initiation.
We next examined the polysome profiles of TORdepleted cells using the torts strain NB35. Again, a severe reduction in the number of polysomes and a coincident increase in the 80S peak were evident after incubation for 5 h at the nonpermissive temperature ( Figure 5C ). A similar but less pronounced effect was observed after 3 h at the nonpermissive temperature. Thus, TOR is required for translation initiation. (Pringle and Hartwell, 1981) , a reduction in protein synthesis to -10% of normal levels, downregulation of CLN3 message (Hubler et al., 1993) , and enlargement of the vacuole (Granot and Snyder, 1991) . As described above, rapamycin-treated or TOR-depleted cells display all these characteristics. Additionally, rapamycin-treated or TOR-depleted cells are still alive (metabolically active) despite the observed reduction in protein synthesis; rapamycin-treated cells exclude the vital dye phloxin B even 24 h after treatment, and all temperature-sensitive tor2 alleles isolated to date are reversible (Barbet and Hall, unpublished data) . This led us to consider that rapamycin might be causing a starvation response despite the presence of nutrients, and inducing cells to enter GO. To test this, we examined by Northern analysis the effect of rapamycin on the transcription of genes whose mRNA levels are known to change upon entry into GO. The heat shock genes SSA3 and HSP26 and the ubiquitin gene UBI4 are transcriptionally induced upon entry into GO (Werner-Washburne et al., 1993) . The catalase T gene CTT1 is also transcriptionally induced upon entry into GO, with enzymatic activity peaking and then declining 3 h after cells enter stationary phase (Werner-Washburne et al., 1993 ). In contrast, the mRNA level of the heat shock genes SSA1 and SSA2 (SSA1/2) fluctuates in different ways depending on the starvation regimen but can remain largely unchanged, and transcription of the cold-inducible "heat shock" genes SSB1 and SSB2 (SSB1/2) is severely repressed upon entry into GO (Werner-Washburne et al., 1993) . As shown in Figure 6A , we observed these same changes in transcription upon rapamycin treatment. The mRNAs for SSA3, HSP26, and UBI4 were induced upon rapamycin treatment; maximal induction occurred 2 h after rapamycin addition for SSA3 and HSP26, and after 30 min for UBI4. The CTT1 transcript was also induced upon rapamycin treatment, and transcript levels remained high for 2 h before falling. In contrast, the SSB1/2 transcripts decreased to almost undetectable levels within 1 h of treatment. The level of SSA1/2 transcripts fluctuated but remained largely unchanged. Thus, it appears that rapamycin causes a starvation response and induces entry into GO. We next examined whether TOR depletion elicits the same starvation-induced changes in transcript levels. We could not utilize the torts strain for these experiments, because many of the same changes in transcript levels occur normally at high temperature (the nonpermissive temperature of our tortS mutant) independently of starvation. Therefore, we used a strain containing TOR2 under control of the regulatable GALl promoter and chromosomal disruptions of both TOR1 and TOR2 (JK350-21a) to deplete the cells of TOR Helliwell et al., 1994) . After shifting from galactose-(SGal/Gly) to glucose-containing (SD) medium (TOR-depletion conditions), we observed changes in the pattern of transcription similar to those seen when wild-type cells are treated with rapamycin ( Figure 6B ). Thus, TOR depletion also induces a starvation response.
Additional indicators of stationary phase are the accumulation of the storage carbohydrate glycogen and acquisition of thermotolerance. We examined whether cells treated with rapamycin accumulate glycogen. Cultures were treated for 5 h with rapamycin, harvested by filtration at hourly intervals, and stained for glycogen using iodine vapor, which stains glycogen-containing cells dark brown (Chester, 1968) . As shown in Figure 6C for the 5-h time point, cells treated with rapamycin did indeed stain darkly when exposed to iodine. Accumulation of glycogen was weakly detectable after 1 h of treatment. Also confirming that loss of TOR function induces a starvation response, we observed that cells depleted for TOR exhibit increased resistance to the killing effects of high temperatures when compared with wild-type cells (our unpublished results). The RAS/cAMP signal transduction pathway acts in early Gl (before the mating pheromone arrest point) and may be involved in the controlled entry into GO (Broach, 1991; Thevelein, 1994) . To investigate Conditions of the galactose to glucose shift were as described (Helliwell et al., 1994) . Hatched bars correspond to a wild-type (JK9-3da) strain; solid bars correspond to a TOR-depleted strain (JK350-21a). Transcript levels were normalized to ACTI mRNA levels. whether loss of TOR function induces entry into GO by inhibiting the RAS/cAMP cascade, we constitutively activated this pathway, and then tested for abrogation of the rapamycin-induced cell cycle arrest. Two methods were used to constitutively activate the pathway. First, we disrupted the BCY1 gene . A BCY1 disruption activates the RAS/cAMP pathway by eliminating the negative regulatory subunit of the cAMP-dependent protein kinase A (Cannon and Tatchell, 1987; Toda et al., 1987) . Second, we introduced the dominant, activated RAS2 allele RAS2valI9. The RAS2vall9 mutation hyperactivates the RAS/cAMP pathway by maintaining RAS2 in its active, GTP-bound state (Kataoka et al., 1984) . Both bcyl (NB30) and RAS2ValI9 (NB34) cells were as sensitive as wild-type cells to rapamycin, based upon growth arrest in the presence of drug. Flow cytometry on these strains indicated that greater than 85% of the cells arrested with a in DNA content after 3 h of rapamycin treatment, as observed with wild-type cells (see Figure 1 for wild-type cells). Rapamycin-treated bcyl and RAS2ValI9 cells also accumulated glycogen, as determined by iodine staining. Therefore, activation of the RAS/cAMP pathway does not abrogate the rapamycin-induced cell cycle arrest, indicating that TOR is not part of the RAS/cAMP pathway.
Our data do not rule out the possibility that TOR lies in the RAS/cAMP pathway downstream of BCY1, but we consider this very unlikely. First, subcellular localization studies (Kunz, Stevenson, Schneider, and Hall, unpublished data) and their homology to lipid kinases indicate that the TORs are membrane-associated proteins, whereas BCY1 is a membrane-distal component of the RAS/cAMP pathway. Second, diploid cells lacking TOR function arrest in Gl (2n DNA content) but do not sporulate, whereas diploids compromised in the RAS/ cAMP pathway do sporulate. Third, activation of p70 S6 kinase, a presumed downstream component of TOR in mammalian cells, is independent of p2lras (Downward, 1994; Ming et al., 1994) . Fourth, there is no example of, or need for, a lipid kinase in a signaling pathway that utilizes cAMP as a second messenger; the lipid kinases mediate production of the fundamentally different, phosphatidylinositolderived second messengers. Thus, TOR1 and TOR2 appear to define a novel nutrient-related process mediating progression through early Gi. This would be in agreement with the observations of Cameron et al. (1988) , who described mutants that express low-level, constitutive cAMP-dependent protein kinase A activity but that still respond appropriately to nutrient conditions, even in the absence of essential upstream components of the RAS/cAMP pathway.
Expression of CLN3 under Altered Translational Control Confers TOR-independent GI Progression
The finding that loss of TOR function causes an early reduction in protein synthesis and a Gi arrest within one generation suggested that TOR might be controlling translation of an unstable protein(s) required for Gi progression. Good candidates for such proteins were the Gi cyclins, as these proteins are unstable and limiting for Gi progression (Cross, 1988; Nash et al., 1988; Hubler et al., 1993; Tyers et al., 1993) . To test whether cells lacking TOR function arrest in early Gl (GO) because they do not synthesize Gi cyclins, we devised a situation in which one of these, CLN3, would be synthesized upon rapamycin treatment, and asked whether this would be sufficient to drive rapamycin-treated cells through Gi. CLN3 was chosen because the transcript for this cyclin is normally present under conditions of rapamycin treatment (Figure 3) . We fused the CLN3 open reading frame to the 5' region (untranslated leader and promoter) of the UBI4 gene. The UBI4 5' region was chosen because it is both transcriptionally and translationally active in GO and would therefore express CLN3 upon rapamycin treatment (Finley et al., 1987; Brenner et al., 1988; Werner-Washburne et al., 1993) (Figure 6A ). We then examined whether the UBI4-CLN3 fusion suppresses the rapamycin-induced cell cycle arrest.
An asynchronously growing wild-type yeast strain containing the UBI4-CLN3 fusion on a centromeric plasmid (NB36) was treated with rapamycin, and at hourly intervals the DNA content of the cells was analyzed by flow cytometry. Like a control strain (NB37) containing a plasmid-borne UBI4 5' region without the CLN3 open reading frame, NB36 cells arrested growth after approximately 2 h of rapamycin treatment. This was expected because rapamycin causes a general inhibition of protein synthesis (Figure 4) , and TOR has an essential non-cell cycle function in addition to its essential role in Gi . Analysis of DNA content of the arrested cells, however, indicated that NB36 (UBI4-CLN3) arrested throughout the cell cycle, whereas the control strain arrested in Gi (Figure 7) . Thus, cells containing the UBI4-CLN3 fusion no longer arrest in Gi upon rapamycin treatment.
Northern analysis of the strain (NB36) containing the UBI4-CLN3 fusion indicated that it produces approximately 20-fold more CLN3 mRNA upon rapamycin treatment than an isogenic strain lacking the fusion. To determine whether the suppression of the cell cycle arrest in strain NB36 was due to altered control of CLN3 translation or merely to the increased dosage of the CLN3 transcript, we examined whether cells containing the wild-type CLN3 gene on a high-copynumber plasmid (NB38) also arrested outside of GI upon rapamycin treatment. After 2 h of treatment, CLN3 (our unpublished results). Furthermore, an integrated copy of the CLN3-1 allele (strain NB33), which bears a mutation that stabilizes the CLN3 protein but does not otherwise affect its cyclin function (Cross, 1988; Nash et al., 1988) , had the same effect as UBI4-CLN3 in causing a random arrest upon rapamycin treatment. This confirms that the UBI4-CLN3 fusion does not promote Gl progression simply because of an elevated level of CLN3 transcripts.
To determine more directly whether rapamycintreated cells containing the UBI4-CLN3 fusion are able to traverse the Gl phase of the cell cycle, we examined the effect of rapamycin on synchronized cells. Strain NB36 (UBI4-CLN3) and the control strain NB37 were synchronized at START by addition of a-factor. Following release from the pheromone block, the cultures were split into two and rapamycin was added to one half, the remaining halves receiving drug vehicle alone. As shown in Figure 7C , NB37 control cells treated with rapamycin entered Gl and arrested as unbudded cells. Rapamycin-treated NB36 (UBI4-CLN3), however, entered Gl but then began to produce new buds before arresting growth, indicating that cells were traversing Gl and beginning a new cycle. Analysis of the arrested cells by flow cytometry confirmed that the NB36 (UBI4-CLN3) cells had traversed Gl whereas the NB37 control cells had not ( Figure 7D ). Thus, UBI4 leader-dependent expression of CLN3 causes rapamycin-treated cells to traverse Gi.
Expression of UBI4-CLN3 Confers Starvation Sensitivity
The finding that TOR may normally modulate synthesis of CLN3 (among other proteins) as part of a starvation response suggested that cells containing the UBI4-CLN3 fusion might be sensitive to starvation. To test this suggestion, UBI4-CLN3 strain NB36 and control strain NB37 were grown to stationary phase (starved) and samples were removed daily for assessment of cell viability and the percentage of budded cells. As NB36 (UBI4-CLN3) cells entered stationary phase (cell number no longer increased) ( Figure 8A ), their ability to form colonies on rich medium rapidly decreased ( Figure 8B ). In contrast, starved NB37 control cells retained high viability for the duration of the experiment. The starvation sensitivity of NB36 (UBI4-CLN3) was most likely due to this strain's inability to arrest in Gl (GO), as suggested by the observations that it stopped dividing at a higher cell density (-1.5-fold) than the control strain ( Figure 8A ) and with a high percentage of budded cells ( Figure 8C ). Strain NB38 containing the wild-type CLN3 gene in high dosage behaved in this experiment like control strain NB37. These findings support the involvement of TOR in nutrient sensing, and also confirm that modulating the level of translation is part of the regulated entry into stationary phase (GO). DISCUSSION We have shown that loss of TOR function (rapamycin treatment or TOR depletion) causes yeast cells to arrest in early Gl and to exhibit, by all criteria examined, characteristics of starved cells entering stationary phase, or GO. We have also demonstrated that loss of TOR function causes a general inhibition of translation initiation. Providing the transcript for the Gi cyclin CLN3 under the translational control of the UBI4 5' region suppresses the rapamycin-induced Gl arrest and confers starvation sensitivity. These results suggest the following model for the role of TOR in cell cycle control (Figure 9 ). In response to nutrient availability, TOR stimulates general translation initiation, including translation of Gi-regulatory transcripts such as those for CLN3 and other Gi cyclins. This then drives cells through Gi and into S phase. In the converse situation, the absence of nutrients causes inactivation of TOR, which leads to loss of translation and a subsequent early Gi arrest and entry into GO. It is important to emphasize that TOR is required for general translation and that the role of TOR in cell cycle control, as proposed here, is just part of a greater role in general growth control. We would also like to stress that, although it accounts for all our data, the model is largely speculative and is intended only as a framework to bring together our and other findings.
Several lines of evidence suggest that TOR is part of a signaling pathway. First, the TORs are homologous to PI kinases, enzymes implicated in signaling. Second, because loss of TOR rapidly causes a starvation response, TOR is likely involved in sensing and relaying the availability of nutrients. Indeed, constitutively activating the proposed pathway by providing CLN3 independently of upstream components (CLN3 under the translational control of the UBI4 untranslated leader) causes starvation sensitivity. Third, the mammalian counterpart of TOR (FRAP/RAFT1/RAPT1/ mTOR) appears to mediate an intermediate step in a defined, rapamycin-sensitive signal transduction pathway required for cell proliferation (Brown et al., 1994; Chiu et al., 1994; Downward, 1994; Sabatini et al., 1994; Sabers et al., 1995) . The putative TOR pathway is novel because it acts in early Gl, and TOR is not part of the RAS/cAMP pathway.
The observed inhibition of translation initiation is likely a direct consequence of loss of TOR function and the cause (rather than an effect) of the cell cycle arrest, for the following reasons. First, the reduction in translation is the earliest effect observed upon loss of TOR function. Second, a specific block in translation initiation, either by mutation of an initiation factor or by treatment with a low concentration of cyclo-N.C. Barbet et al. heximide, causes yeast cells to arrest in early Gi (Hartwell and Unger, 1977; Johnston et al., 1977; Pringle and Hartwell, 1981; Hanic-Joyce et al., 1987; Brenner et al., 1988; Hubler et al., 1993; Barnes et al., 1995) . Third, and most important, allowing translation initiation of an appropriate, cell cycle-controlling transcript is sufficient to suppress the rapamycin-induced Gl arrest. Fourth, TOR in mammalian cells probably activates translation initiation and Gl progression in response to mitogens (Downward, 1994; see INTRODUCTION) . Thus, the TOR pathway in yeast appears to control translation initiation and, thereby, early Gl progression. The observation that phosphorylation of the yeast equivalent of S6 (S10) is not important for growth (Zinker and Warner, 1976; Kruse et al., 1985; Johnson and Warner, 1987) suggests that TOR is not regulating translation initiation in yeast through S6 (see INTRODUCTION) . One alternative possibility is that the TOR pathway controls translation initiation through the initiation factor eIF-4E (or an associated subunit). eIF-4E is the cap-binding subunit of the eIF-4F complex, which also contains eIF-4A, an RNA helicase, and eIF-4y, a protein of unknown function (Rhoads, 1988; Lanker et al., 1992; Linder, 1992; Goyer et al., 1993; Redpath and Proud, 1994) . eIF-4F binds to the 5' cap structure of mRNA and promotes unwinding of 5' secondary structure, facilitating binding of the 43S ribosomal preinitiation complex to the mRNA. Several observations suggest that TOR could control eIF-4E. First, analyses of CDC33 (encodes eIF-4E) and TOR mutants indicate that eIF-4E and TOR have remarkably similar roles. Both have essential functions required for general translation initiation (Altmann et al., 1989; see RESULTS) . Furthermore, both have an early Gl-specific function and an essential function that is not Gl specific (Johnston et al., 1977; Pringle and Hartwell, 1981; Brenner et al., 1988; ; protein synthesis is required at several points in the cell cycle but is most limiting in GI (Burke and Church, 1991) . Second, in mammalian cells, eIF-4E is the rate-limiting protein in translation (Duncan et al., 1987) and a target for regulation. Growth factors activate protein synthesis by triggering the phosphorylation and release of the eIF-4E- Gi progression Figure 9 . Model of the TOR pathway in cell cycle control. Rapamycin (R) forms a complex with FKBP to inhibit TOR (Heitman et al., 1993; . TOR is TOR1 and TOR2. PI is phosphatidylinositol. See DISCUSSION for further details. Because TOR is required for general translation (see RESULTS), the role of TOR in cell cycle control is just part of a greater role in general growth control; the model proposed here focuses exclusively on that part of TOR's role in general growth control that affects progression through the Gl phase of the cell cycle.
inhibiting factor 4E-BP1 /PHAS-I Hu et al., 1994; Lin et al., 1994; Pause et al., 1994) . Importantly, rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation (Beretta et al., 1996) . Third, in proliferating yeast and mammalian cells, eIF-4E and an associated subunit are phosphorylated and therefore potentially subject to regulation by this type of modification (Duncan et al., 1987; Joshi-Barve et al., 1990; Morley et al., 1991; Rhoads et al., 1993; Redpath and Proud, 1994; Zanchin et al., 1994) . Fourth, translation of UBI4 appears to have, at least, reduced dependence on eIF-4E (Brenner et al., 1988) . Thus, the block in translation initiation caused by loss of TOR function may be due to a down regulation of eIF-4E.
